{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:26:53Z","timestamp":1790890013879,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/inf.0b013e3181e2189d","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T22:07:42Z","timestamp":1273183662000},"page":"940-944","source":"Crossref","is-referenced-by-count":31,"title":["A Chewable Pediatric Fixed-dose Combination Tablet of Stavudine, Lamivudine, and Nevirapine"],"prefix":"10.1097","volume":"29","author":[{"given":"Nirun","family":"Vanprapar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim R.","family":"Cressey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulkanya","family":"Chokephaibulkit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella","family":"Muresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nottasorn","family":"Plipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virat","family":"Sirisanthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasana","family":"Prasitsuebsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchat","family":"Hongsiriwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawee","family":"Chotpitayasunondh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achara","family":"Eksaengsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MariPat","family":"Toye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Elizabeth","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Yogev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210202","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1086\/430714","article-title":"Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.","volume":"41","author":"Puthanakit","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R2-11-20210202","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ijid.2007.10.008","article-title":"Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.","volume":"12","author":"Lapphra","year":"2008","journal-title":"Int J Infect Dis"},{"key":"R3-11-20210202","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1097\/01.aids.0000247117.66585.ce","article-title":"In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy.","volume":"20","author":"O'Brien","year":"2006","journal-title":"AIDS"},{"key":"R4-11-20210202","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/01.aids.0000183625.97170.59","article-title":"Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.","volume":"19","author":"Chokephaibulkit","year":"2005","journal-title":"AIDS"},{"key":"R5-11-20210202","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/INF.0b013e31818dd72b","article-title":"Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.","volume":"28","author":"Puthanakit","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R6-11-20210202","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/INF.0b013e318125720a","article-title":"Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand.","volume":"26","author":"Puthanakit","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R9-11-20210202","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1128\/AAC.45.3.758-763.2001","article-title":"Determination of dosing guidelines for stavudine (2\u2032,3\u2032-didehydro-3\u2032-deoxythymidine) in children with human immunodeficiency virus infection.","volume":"45","author":"Kaul","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-11-20210202","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199936010-00004","article-title":"Clinical pharmacokinetics of lamivudine.","volume":"36","author":"Johnson","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R11-11-20210202","article-title":"Viramune [package insert].","year":"2005"},{"key":"R13-11-20210202","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/08892220260190290","article-title":"Position paper on therapeutic drug monitoring of antiretroviral agents.","volume":"18","author":"Acosta","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R14-11-20210202","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00007691-200306000-00023","article-title":"Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.","volume":"25","author":"Droste","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R15-11-20210202","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.ftd.0000211817.58052.b8","article-title":"Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring.","volume":"28","author":"Holland","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R16-11-20210202","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00002030-200106150-00003","article-title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.","volume":"15","author":"Veldkamp","year":"2001","journal-title":"AIDS"},{"key":"R17-11-20210202","article-title":"Stavudine (Zerit) [package insert].","year":"2006"},{"key":"R19-11-20210202","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00003088-200140090-00005","article-title":"Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.","volume":"40","author":"Bruno","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R20-11-20210202","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAD.0b013e3280117ca0","article-title":"Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.","volume":"21","author":"Hosseinipour","year":"2007","journal-title":"AIDS"},{"key":"R21-11-20210202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.qai.0000199098.95967.ab","article-title":"A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.","volume":"41","author":"Vezina","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-11-20210202","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/QAD.0b013e3282f4a208","article-title":"Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.","volume":"22","author":"L'Homme","year":"2008","journal-title":"AIDS"},{"key":"R23-11-20210202","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/sj.clpt.6100118","article-title":"Age-dependent pharmacokinetics of lamivudine in HIV-infected children.","volume":"81","author":"Burger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R24-11-20210202","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/00003088-200342060-00009","article-title":"Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.","volume":"42","author":"de Vries-Sluijs","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R25-11-20210202","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1345\/aph.1E563","article-title":"Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.","volume":"39","author":"Duong","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R26-11-20210202","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/00002030-200307250-00008","article-title":"Nevirapine use in HIV-1-infected children.","volume":"17","author":"Verweel","year":"2003","journal-title":"AIDS"},{"key":"R29-11-20210202","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/infdis\/174.4.713","article-title":"Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.","volume":"174","author":"Luzuriaga","year":"1996","journal-title":"J Infect Dis"},{"key":"R30-11-20210202","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/infdis\/167.1.21","article-title":"2\u2032,3\u2032-didehydro-3\u2032-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial.","volume":"167","author":"Browne","year":"1993","journal-title":"J Infect Dis"},{"key":"R31-11-20210202","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1542\/peds.114.2.e235","article-title":"Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.","volume":"114","author":"Taylor","year":"2004","journal-title":"Pediatrics"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0b013e3181e2189d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:22:29Z","timestamp":1786040549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201010000-00011"}},"subtitle":["Pharmacokinetics and Safety Compared With the Individual Liquid Formulations in Human Immunodeficiency Virus-infected Children in Thailand"],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3181e2189d","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}